Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (31-40 of 194) with videos related to

Pageof 20
Sort By:
Bulletin Du Cancer|January 1, 1987
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast]J Bonneterre, J M Pion, A Demaille
European Journal of Cancer (Oxford, England : 1990)|November 3, 1998
ERBB2 oncogene in human breast cancer and its clinical significanceF Révillion, J Bonneterre, J P Peyrat
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1990
Growth factors and oncogenes in human solid tumors: clinical aspectsJ Bonneterre, J P Peyrat, A Demaille
British Journal of Cancer|July 4, 1998
Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapyJ P Peyrat, F Révillion, J Bonneterre
Anticancer Research|July 1, 1995
Urinary excretion of deoxypyridinoline in patients with breast cancerM Nguyen-Pamart, J Bonneterre, B Hecquet
Neuro-Chirurgie|January 1, 1982
[Neurologic manifestations of spinal plasmacytomas]F Lesoin, J Bonneterre, A Lesoin, et al.
Bulletin Du Cancer|January 1, 1984
[Variations in gamma-glutamyltranspeptidase levels in patients receiving hormone therapy with aminoglutethimide]J Bonneterre, M Nguyen, B Hecquet, et al.
Gynecologie, Obstetrique & Fertilite|January 14, 2014
[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?]A Turpin, A Mailliez, P Vennin, et al.
Bulletin Du Cancer|January 1, 1985
[Aminoglutethimide-induced dyslipidemia. Experimental study]M Nguyen, J Bonneterre, J Vanlerenberghe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2010
Silent hereditary hematochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failureN Penel, A Adenis, A Mailliez, et al.
Pageof 20

Showing results (31-40 of 194) with videos related to

Sort By:
Pageof 20
Bulletin Du Cancer|January 1, 1987
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast]J Bonneterre, J M Pion, A Demaille
European Journal of Cancer (Oxford, England : 1990)|November 3, 1998
ERBB2 oncogene in human breast cancer and its clinical significanceF Révillion, J Bonneterre, J P Peyrat
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1990
Growth factors and oncogenes in human solid tumors: clinical aspectsJ Bonneterre, J P Peyrat, A Demaille
British Journal of Cancer|July 4, 1998
Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapyJ P Peyrat, F Révillion, J Bonneterre
Anticancer Research|July 1, 1995
Urinary excretion of deoxypyridinoline in patients with breast cancerM Nguyen-Pamart, J Bonneterre, B Hecquet
Neuro-Chirurgie|January 1, 1982
[Neurologic manifestations of spinal plasmacytomas]F Lesoin, J Bonneterre, A Lesoin, et al.
Bulletin Du Cancer|January 1, 1984
[Variations in gamma-glutamyltranspeptidase levels in patients receiving hormone therapy with aminoglutethimide]J Bonneterre, M Nguyen, B Hecquet, et al.
Gynecologie, Obstetrique & Fertilite|January 14, 2014
[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?]A Turpin, A Mailliez, P Vennin, et al.
Bulletin Du Cancer|January 1, 1985
[Aminoglutethimide-induced dyslipidemia. Experimental study]M Nguyen, J Bonneterre, J Vanlerenberghe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2010
Silent hereditary hematochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failureN Penel, A Adenis, A Mailliez, et al.
Pageof 20